纾萎方治疗慢性萎缩性胃炎的临床研究

目的]观察纾萎方治疗慢性萎缩性胃炎（CAG）的临床疗效和安全性。方法]采用随机与阳性对照药平行对照的方法，将81例CAG患者分为治疗组（纾萎方）41例，对照组（胃复春）40例。观察2组临床症状改善情况及病理检查胃黏膜腺体萎缩、肠上皮化生（IM）、异型增生（ATP）和幽门螺杆菌（Hp）感染的变化。结果]病理疗效：治疗组总有效率75．61％，对照组50．00％（P〈0．05）；症候疗效：治疗组总有效率95．12％，对照组47．50％（P〈0．01）。结论]纾萎方治疗CAG不仅能明显改善临床症状，而且对CAG、IM及ATP有逆转作用，并有效提高CAG胃黏膜腺体形态的恢复质量。

Clinical research of Shuweifang on treating patients with chronic atrophic gastritis

Objeetive] To observe the efficacy and safety of Shuweifang on the treatment of CAG. Methods]Eightyone patients with CAG were divided into two groups in a randomized and appositive drug-controlled clinical trail. Forty one cases in the treatment group were treated with CAG and forty cases in the control group were treated with Weifuchun. The change of clinical symptom was observed. Atrophy of glandular organ in gastric mucosa, intestinal metaplasia （IM）,atypical hyperplasia（ATP） and helicobacter pyloric infection were observed by gastroscope and biopsy of gastric mucosa. Results]The total effective rate of Shuweifang group and Weifuchun group in improving pathological changes were 75. 61% and 50.00% respectively. There was a significantly statistical difference between the two groups（P〈0.05）. The total effective rate of the treatment group and the control group in ameliorating symptoms were 95. 12% and 47. 50%. The statistics results showed significant difference between the two groups （P〈0. 01）. Neither serious side effects nor cancerous lesion of CAG were found during the processes of clinical therapy. Conclusion]Shuweifang greatly improves the clinical symptoms and gastric mucosa pathology of patients with CAG, IM and ATP, and improved effectively recoverable quality of morphology of glandular organ in gastric mucosa of CAG.